2023
Risk Factors for Perinatal Transmission of Hepatitis C Virus
Prasad M, Saade G, Clifton R, Sandoval G, Hughes B, Reddy U, Bartholomew A, Salazar A, Chien E, Tita A, Thorp J, Metz T, Wapner R, Sabharwal V, Simhan H, Swamy G, Heyborne K, Sibai B, Grobman W, El-Sayed Y, Casey B, Parry S, Rathore M, Diaz-Velasco R, Puga A, Wiznia A, Kovacs A, Garry D, Macones G. Risk Factors for Perinatal Transmission of Hepatitis C Virus. Obstetrics And Gynecology 2023, 142: 449-456. PMID: 37590978, PMCID: PMC10437102, DOI: 10.1097/aog.0000000000005306.Peer-Reviewed Original ResearchConceptsPerinatal transmissionHCV infectionRisk factorsPrimary outcomeHuman Development Maternal-Fetal Medicine Units NetworkMaternal-Fetal Medicine Units NetworkHepatitis C virus infectionEunice Kennedy Shriver National InstituteC virus infectionPerinatal transmission rateWeeks of gestationHigh viral loadHepatitis C virusMonths of lifePositive test resultsAntepartum bleedingViremic participantsVaginal bleedingHCV RNAViremic individualsViral loadC virusObservational studyVirus infectionDemonstrable viremia
2022
Determining the lower limit of detection required for HCV viral load assay for test of cure following direct‐acting antiviral‐based treatment regimens: Evidence from a global data set
Morgan JR, Marsh E, Savinkina A, Shilton S, Shadaker S, Tsertsvadze T, Kamkamidze G, Alkhazashvili M, Morgan T, Belperio P, Backus L, Doss W, Esmat G, Hassany M, Elsharkawy A, Elakel W, Mehrez M, Foster GR, Kinge C, Chew KW, Chasela CS, Sanne IM, Thanung YM, Loarec A, Aslam K, Balkan S, Easterbrook PJ, Linas BP. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct‐acting antiviral‐based treatment regimens: Evidence from a global data set. Journal Of Viral Hepatitis 2022, 29: 474-486. PMID: 35278339, PMCID: PMC9248016, DOI: 10.1111/jvh.13672.Peer-Reviewed Original ResearchConceptsDetectable viraemiaDetectable HCV RNALow-level viraemiaVirological treatment failureHCV viral loadTest of cureHepatitis C virusViral load assaysHCV viraemiaHCV RNATreatment failureViral loadC virusClinical trialsMinimal fibrosisSVR12ViraemiaGlobal eliminationLogistic regressionDiagnostic performanceLevel of detectionObservational databaseIULaboratory-based assaysCure
2021
HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
Morgan JR, Savinkina A, Pires dos Santos AG, Xue Z, Shilton S, Linas B. HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients. Advances In Therapy 2021, 38: 1690-1700. PMID: 33590445, PMCID: PMC7932931, DOI: 10.1007/s12325-021-01647-4.Peer-Reviewed Original ResearchConceptsMean HCV RNA levelHCV RNA levelsVirologic failureIU/HCV RNARNA levelsPost-treatment week 4Hepatitis C cureMean HCV RNATreatment virologic failureLevel of viremiaDirect acting antiviralsHCV viral loadTime of relapseResource-limited settingsTreatment failureViral loadElimination targetsClinical trialsWeek 4PatientsCare testOverall populationCare assaysLarger study
2019
Screening for HBV, HCV, HIV and syphilis infections among bacteriologically confirmed tuberculosis prisoners: An urgent action required
Puga M, Bandeira L, Pompilio M, de Rezende G, Soares L, de Castro V, Tanaka T, Cesar G, de Oliveira S, Teles S, Yassuda R, dos Santos Weis-Torres S, Basílio S, Croda J, Motta-Castro A. Screening for HBV, HCV, HIV and syphilis infections among bacteriologically confirmed tuberculosis prisoners: An urgent action required. PLOS ONE 2019, 14: e0221265. PMID: 31437184, PMCID: PMC6705821, DOI: 10.1371/journal.pone.0221265.Peer-Reviewed Original ResearchConceptsHepatitis B virusSyphilis infectionViral hepatitisHIV infectionB virusAnti-HCV positive samplesChronic hepatitis B virusFirst-line anti-tuberculosis drugsLifetime syphilis infectionCases of tuberculosisAnti-TB drugsCross-sectional studyPublic health problemAnti-tuberculosis drugsCurrent HCVHCV exposureHCV RNAHepatitis testingTuberculosis infectionActive syphilisSerological markersEpidemiological featuresFrequent causeSide effectsHCVPlatelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis
Sayyar M, Saidi M, Zapatka S, Deng Y, Ciarleglio M, Garcia‐Tsao G. Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis. Liver International 2019, 39: 2061-2065. PMID: 31365178, PMCID: PMC11340272, DOI: 10.1111/liv.14203.Peer-Reviewed Original ResearchConceptsChronic hepatitis C virusHepatitis C virusPresence of cirrhosisViral eliminationTreatment completionPlatelet countLiver fibrosisNegative HCV RNAAbsence of cirrhosisChronic HCV infectionNon-invasive scoresPlatelet count increaseChronic liver diseaseHCV infectionPortal hypertensionHCV RNAAntiviral treatmentFibrosis scoreLiver diseaseC virusFibrosis stageRetrospective analysisCirrhosisPatientsFibrosis
2018
Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era
Sacks‐Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME. Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era. Journal Of The International AIDS Society 2018, 21: e25051. PMID: 29633559, PMCID: PMC5978682, DOI: 10.1002/jia2.25051.Peer-Reviewed Original ResearchConceptsCo-infected populationHIV co-infected populationElimination initiativeHCV eliminationHIV/HCV co-infected populationCare dataHCV treatment uptakeSustained virological responseHalf of patientsDAA eraDAA treatmentHCV careSVR ratesVirological responseHCV infectionHCV treatmentHCV RNAImplementation science frameworkTreatment uptakeHigh-income countriesHIVIntervention characteristicsTreatment availabilityDiagnosis rateElimination programIs There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies?
Saadi T, Khoury J. Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies? Journal Of Clinical Gastroenterology 2018, 52: 353-359. PMID: 28590324, DOI: 10.1097/mcg.0000000000000853.Peer-Reviewed Original ResearchConceptsDirect antiviral agentsAdverse eventsHepatocellular carcinomaAntiviral agentsChronic hepatitis C virus (HCV) infectionParitaprevir/ritonavir/ombitasvirHepatitis C virus infectionDe novo hepatocellular carcinomaLarge clinical trial dataSerum HCV RNAC virus infectionNovo hepatocellular carcinomaTreatment of choiceTransitional cell carcinomaAggressive hepatocellular carcinomaAggressive transitional cell carcinomaClinical trial dataDevelopment of malignancyHCV infectionHCV RNAHCV genotypesLiver diseaseCell carcinomaLaryngeal carcinomaPancreatic adenocarcinomaA172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT)
Conway B, Dore G, Altice F, Litwin A, Grebely J, Dalgard O, Gane E, Shibolet O, Luetkemeyer A, Nahass R, Peng C, Gendrano I, Huang H, Chen E, Nguyen B, Wahl J, Barr E, Robertson M, Platt H. A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT). Journal Of The Canadian Association Of Gastroenterology 2018, 1: 299-300. PMCID: PMC6508009, DOI: 10.1093/jcag/gwy008.173.Peer-Reviewed Original ResearchEnd of treatmentImmediate treatment groupHCV reinfectionProbable reinfectionHCV RNATreatment groupsLong-term response ratesHepatitis C virus genotypesEBR/GZRHCV reinfection ratesUndetectable HCV RNARisk of reinfectionC virus genotypesInterferon-free HCV treatmentRate of reinfectionFixed-dose combinationPost-treatment samplesRecurrent viremiaReinfection incidenceAgonist therapyDaily regimenHCV therapyHCV treatmentVirologic failureHCV GT1
2017
Tylophorine Analogs Allosterically Regulates Heat Shock Cognate Protein 70 And Inhibits Hepatitis C Virus Replication
Wang Y, Lee S, Ha Y, Lam W, Chen SR, Dutschman GE, Gullen EA, Grill SP, Cheng Y, Fürstner A, Francis S, Baker DC, Yang X, Lee KH, Cheng YC. Tylophorine Analogs Allosterically Regulates Heat Shock Cognate Protein 70 And Inhibits Hepatitis C Virus Replication. Scientific Reports 2017, 7: 10037. PMID: 28855547, PMCID: PMC5577180, DOI: 10.1038/s41598-017-08815-z.Peer-Reviewed Original ResearchConceptsHepatitis C virus replicationC virus replicationTylophorine analogsHCV replicationHeat shock cognate protein 70HCV RNAShock cognate protein 70Inhibits Hepatitis C Virus ReplicationVirus replicationProtein 70Anti-HCV activityHCV replication complexPotent inhibitory activityExhibit potent inhibitory activityInhibitory activityATPase activityArthritisInflammationLupusReplicationActivityCancerHsc70Prevalence and Incidence of HCV Infection among Prisoners in Central Brazil
Puga M, Bandeira L, Pompilio M, Croda J, de Rezende G, Dorisbor L, Tanaka T, Cesar G, Teles S, Simionatto S, Novais A, Nepomuceno B, Castro L, do Lago B, Motta-Castro A. Prevalence and Incidence of HCV Infection among Prisoners in Central Brazil. PLOS ONE 2017, 12: e0169195. PMID: 28060860, PMCID: PMC5218405, DOI: 10.1371/journal.pone.0169195.Peer-Reviewed Original ResearchConceptsHCV infectionCohort studyHCV RNASectional studyInjecting-drug useNew HCV infectionsHCV risk behaviorsCross-sectional studyHCV exposureHepatitis CHIV positivityEffective intervention strategiesAssociated FactorsClinical evaluationIndependent associationOverall prevalenceRisk factorsIncidence rateBlood samplesDrug useNew casesRisk behaviorsInfectionHigh frequency ratePrevalence
2016
Disparities in hepatitis C testing in U.S. veterans born 1945–1965
Sarkar S, Esserman DA, Skanderson M, Levin FL, Justice AC, Lim JK. Disparities in hepatitis C testing in U.S. veterans born 1945–1965. Journal Of Hepatology 2016, 65: 259-265. PMID: 27130843, PMCID: PMC4955712, DOI: 10.1016/j.jhep.2016.04.012.Peer-Reviewed Original ResearchConceptsUnited States Preventative Services Task ForceHCV testingHCV antibodiesRisk factorsHepatitis C virus testingHepatitis C virus infectionHealth systemVeterans Administration Health SystemBirth cohort testingHCV testing practicesHepatitis C testingNational screening policyPositive HCV RNAPredictors of testingC virus infectionVA health systemAdvanced liver fibrosisVeterans Administration dataCorporate Data WarehouseHCV positivityHCV RNAAdvanced fibrosisHCV testLiver fibrosisVirus infection
2015
Knockdown of Autophagy Inhibits Infectious Hepatitis C Virus Release by the Exosomal Pathway
Shrivastava S, Devhare P, Sujijantarat N, Steele R, Kwon Y, Ray R, Ray R. Knockdown of Autophagy Inhibits Infectious Hepatitis C Virus Release by the Exosomal Pathway. Journal Of Virology 2015, 90: 1387-1396. PMID: 26581990, PMCID: PMC4719613, DOI: 10.1128/jvi.02383-15.Peer-Reviewed Original ResearchConceptsHepatitis C virusInfectious hepatitis C virusInnate immune responseHCV releaseImmune responseInhibition of HCVVirus-infected hepatocytesExosomal pathwayKnockdown cellsExosome markers CD63Infectious virus particlesBST-2 geneChronic hepatitisRole of autophagyHCV RNALiver cirrhosisHCV pathogenesisC virusInfected hepatocytesViral persistenceHepatocellular carcinomaHCV assemblyMajor causeVirus transmissionPrecise mechanism
2014
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.
Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Annals Of Internal Medicine 2014, 160: 369-79. PMID: 24723077, PMCID: PMC4254786, DOI: 10.7326/m13-1829.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsAscitesBacterial InfectionsCarcinoma, HepatocellularCoinfectionEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHepatitis C, ChronicHIVHIV InfectionsHumansIncidenceLiver NeoplasmsMaleMedication AdherenceMiddle AgedPeritonitisRetrospective StudiesRNA, ViralTreatment OutcomeViral LoadConceptsCo-infected patientsHepatitis C virusHepatic decompensationAntiretroviral-treated patientsCohort studyNonblack raceC virusHepatitis C virus-monoinfected patientsChronic hepatitis C virusHigh rateAntiretroviral therapy eraDetectable HCV RNAIncident hepatic decompensationBaseline hemoglobin levelRetrospective cohort studySpontaneous bacterial peritonitisAdvanced hepatic fibrosisAdvanced liver fibrosisVeterans Health AdministrationDiagnosis of ascitesRate of decompensationTherapy eraHIV RNAVariceal hemorrhageHCV RNA
2013
The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010
Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, Luma H, Charlton M. The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey 2001 through 2010. Journal Of Hepatology 2013, 60: 691-698. PMID: 24291324, DOI: 10.1016/j.jhep.2013.11.014.Peer-Reviewed Original ResearchConceptsNutrition Examination SurveyHCV infectionExamination SurveyNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyThe National Health and Nutrition Examination SurveyLow economic statusAssociated with HCV infectionHepatitis C virus infectionBurden of HCV infectionForeign born personsPrevalence of anti-HCVChronic HCV infectionC virus infectionPrevalence of HCVUnited StatesIncident casesInfected personsNational HealthHIV statusGeneral populationAnti-HCVBlood transfusionHCV RNAHepatitis C
2011
Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation
Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.Peer-Reviewed Case Reports and Technical NotesConceptsLiver allograft rejectionHepatitis C virusRenal graft rejectionAllograft rejectionHCV recurrenceCholestatic hepatitisGraft rejectionHCV RNAPatient survivalEnd-stage liver disease (MELD) scoreOne-year patient survivalIFN/RBV therapyFIBROSING CHOLESTATIC HEPATITISHistologic HCV recurrenceIFN/ribavirinOne-year graftSuccessful salvage strategiesTime of OLTHCV RNA levelsLiver Disease scoreAnti-HCV therapyCohort of patientsEarly graft failureFCH groupOLT recipients
2009
Focal Distribution of Hepatitis C Virus RNA in Infected Livers
Stiffler J, Nguyen M, Sohn J, Liu C, Kaplan D, Seeger C. Focal Distribution of Hepatitis C Virus RNA in Infected Livers. PLOS ONE 2009, 4: e6661. PMID: 19688046, PMCID: PMC2722721, DOI: 10.1371/journal.pone.0006661.Peer-Reviewed Original ResearchConceptsHepatitis C virusHCV RNA levelsHCV RNAHCV replicationRNA levelsBiopsy samplesHCV RNA copy numbersIntrahepatic HCV-RNA levelsISG levelsHepatitis C virus RNAWhole liver sectionsC virus RNAViral RNA levelsFocal distributionInnate immune responseRNA copy numberHCV infectionC virusInfected patientsInfected hepatocytesInterferon betaImmune responseInfected liverLiver sectionsIFNbeta expression
2008
Distribution of Hepatitis C virus (HCV) genotypes in seropositive patients in the state of Alagoas, Brazil
Gonzaga R, Rodart I, Reis M, Neto C, Silva D. Distribution of Hepatitis C virus (HCV) genotypes in seropositive patients in the state of Alagoas, Brazil. Brazilian Journal Of Microbiology 2008, 39: 644-647. PMID: 24031281, PMCID: PMC3768450, DOI: 10.1590/s1517-83822008000400008.Peer-Reviewed Original ResearchAnti-HCV seropositive patientsHepatitis C virus genotypesC virus genotypesSeropositive patientsGenotype 1Genotype 2Nested-reverse transcription-polymerase chain reactionVirus genotypesDetectable HCV RNATranscription-polymerase chain reactionRestriction fragment length polymorphismGenotype-specific primersHCV RNAGenotype 3Subtype 1bSubtype 1aPatientsSerum samplesChain reactionSignificant differencesFragment length polymorphismState of AlagoasLength polymorphismCoinfectionPrevalence
2006
Prevalence of hepatitis C virus (HCV) infection and HCV genotypes of hemodialysis patients in Salvador, Northeastern Brazil
Silva L, Silva M, Rodart I, Lopes G, Costa F, Melo M, Gusmão E, Reis M. Prevalence of hepatitis C virus (HCV) infection and HCV genotypes of hemodialysis patients in Salvador, Northeastern Brazil. Brazilian Journal Of Medical And Biological Research 2006, 39: 595-602. PMID: 16648896, DOI: 10.1590/s0100-879x2006000500005.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionCandidate blood donorsC virus infectionHD patientsHCV infectionBlood donorsGenotype 1Virus infectionAnti-HCV seroprevalenceAnti-HCV prevalenceHCV genotype distributionAnti-HCV antibodiesHCV genotype 1Chronic liver diseaseTransfusion-transmitted infectionsCross-sectional studyDifferent dialysis centresHCV seroprevalenceChronic hemodialysisHemodialysis populationHCV RNAPositive patientsHemodialysis patientsHCV genotypesLiver disease
2005
Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†
Chainuvati S, Khalid S, Kancir S, Shea M, Edwards J, Sernyak M, Wongcharatrawee S, Garcia‐Tsao G. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†. Journal Of Viral Hepatitis 2005, 13: 235-241. PMID: 16611189, DOI: 10.1111/j.1365-2893.2005.00681.x.Peer-Reviewed Original ResearchConceptsCompletion of therapyVirological responsePatient demographicsSubstance useAntiviral therapyMental illnessHepatitis C virus infectionLiver disease characteristicsC virus infectionNIH Consensus ConferenceType of therapyLiver clinicSVR ratesHCV RNAPositive patientsRelative contraindicationTherapy completionTreatment patternsLiver diseaseTreatment eligibilityDisease characteristicsPatient populationPoor adherenceVirus infectionConsensus conference
2004
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C
Abdelmalek M, Firpi R, Soldevila‐Pico C, Reed A, Hemming A, Liu C, Crawford J, Davis G, Nelson D. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transplantation 2004, 10: 199-207. PMID: 14762857, DOI: 10.1002/lt.20074.Peer-Reviewed Original ResearchConceptsHepatitis C virusLiver transplant recipientsTransplant recipientsHepatitis CLiver histologyFibrosis stageHCV RNAViral clearanceViral responseCombination therapyDetectable hepatitis C virusRecurrent chronic hepatitis CRecurrent hepatitis C infectionRecurrent hepatitis C virusDetectable HCV RNASustained viral responseChronic hepatitis CInterferon-based treatmentOrthotopic liver transplantationRecurrent hepatitis CHepatitis C infectionInterferon-based therapyRegression of fibrosisGrade of inflammationBaseline histology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply